zintick
MRVI Maravai LifesciencesAnalyst actions

Keybanc Upgrades Maravai Lifesciences to Overweight, Sets $11.00 Target

The new $11.00 target sits above the $8.00 high among the two firms that rated the stock in the past year.

By Zintick Team · Editor: Kratik Mehta
Published

A close up shot of Pipette filling tray in a laboratory.
Photo: Juice Verve/Shutterstock.com

Key points

  • Keybanc upgraded Maravai Lifesciences to overweight from sector weight with a $11.00 target
  • Before the action, the two firms with targets had a median of $7.25, ranging from $6.50 to $8.00
  • Last close before the action: $7.70 on Nov. 11, up 17.6% over the prior 20 sessions
  • 2025 revenue was $185.7 million, down 28%; latest quarter revenue was $45.9 million, up 10%

Keybanc upgraded Maravai Lifesciences (Nasdaq: MRVI) to overweight from sector weight before the open on Thursday, Nov. 12, and set a price target of $11.00.

Before the upgrade, two firms had rated the stock in the past year, one positive and one neutral. Their median target was $7.25, ranging from $6.50 to $8.00. Keybanc's $11.00 target is above that range.

Maravai's last close before the action was $7.70, on Wednesday, Nov. 11. Over the 20 sessions to that close, the stock rose 17.6%.

For scale, Maravai reported revenue of $185.7 million for 2025, down 28% from the year before. In the latest reported quarter, ended Sept. 30, revenue was $45.9 million, up 10% from a year earlier. Cash and equivalents stood at $73.0 million on that date. The company's market capitalization was about $2.00 billion before the filing.

The upgrade came seven days after the company's Form 10-Q was accepted on Nov. 5.

Sources

Written with AI from analyst rating changes, SEC filings and market data, and checked against those sources before publishing. Our editorial standards.

More analyst ratings

MRVI page →

Filings, figures and price history are on the Maravai Lifesciences page.